

## AmBisome<sup>®</sup> (amphotericin B) – First-time generic

- On February 15, 2022, [Sun Pharmaceuticals launched](#) an [AB-rated](#) generic version of Astellas' [Ambisome \(amphotericin B\)](#) liposome for injection.
- AmBisome is approved for the following:
  - Empirical therapy for presumed fungal infection in febrile, neutropenic patients
  - Treatment of cryptococcal meningitis in HIV-infected patients
  - Treatment of patients with *Aspergillus* species, *Candida* species and/or *Cryptococcus* species infections and
  - Treatment of visceral leishmaniasis.
- Amphotericin B is also available generically as an [injection](#) and as branded [Abelcet<sup>®</sup>](#).
  - Amphotericin B is used to treat progressive, potentially life-threatening fungal infections.
  - Abelcet is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.